BBIO News

Latest breaking news and updates for BBIO stock.

Track all markets on TradingView

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

(NASDAQ:BBIO) PALO ALTO, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on geneti...

Is the vesting schedule likely to create insider selling pressure or affect stock liquidity around the August 2026 vesting dates? What is the estimated expense and cash impact of these RSU grants relative to BridgeBio’s recent compensation trends? How will the additional 139,820 RSUs dilute existing shareholders and impact earnings per share?
Compensation
4 days ago
Read more globenewswire

BridgeBio to Present Phase 2 Proof-of-Concept Data for Encaleret in Post-Surgical Hypoparathyroidism

(NASDAQ:BBIO) PALO ALTO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on geneti...

How does BridgeBio's development timeline and data expectations compare with competitors developing therapies for hypoparathyroidism or related skeletal dysplasias? What is the total addressable market and commercial upside for an oral therapy in post‑surgical hypoparathyroidism versus existing treatments? How will the upcoming Phase 2 proof‑of‑concept data for Encaleret affect BBIO's short‑term stock volatility?
Clinical trials
12 days ago
Read more globenewswire

BridgeBio to Present Additional Open-label Extension Data from ATTRibute-CM at ESC Congress 2025

PALO ALTO, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, ann...

What regulatory or commercial milestones are likely to follow the ESC presentation, and how might they impact the long‑term upside for BBIO? What does the month‑30 open‑label data indicate about efficacy and safety relative to existing ATTR cardiomyopathy treatments, and could it shift market share expectations? How will the new ATTRibute‑CM extension data presented at ESC affect BridgeBio's near‑term stock valuation and trading volume?
Clinical trials
20 days ago
Read more globenewswire